1. Medtech Insight
  2. >>Policy & Regulation

Q4 Recalls Snapshot: Fewer Devices Recalled By Industry, But Software Troubles Still Abound

 
• By Shawn M. Schmitt

Problems with software were the No. 1 reason for medical device recalls in the fourth quarter of 2020. Also: Recalls fell by a modest 3%, but the number of recalled device units mushroomed 158%. Check out our Q4 recalls infographic.

Q4 Device Recalls

The number of product recalls initiated by manufacturers fell slightly in the fourth quarter of 2020 – but there was an increase in the count of recalled device units. There were 235 corrections and removals in Q4, compared to 242 in Q3 – a modest 3% decrease. Meanwhile, industry recalled 59,314,216 units in Q4, a 158% increase from Q3, when 22,951,964 units were pulled from the market. In its State of the Nation 2021 recalls index, business solutions company Sedgwick points out that industry is still having troubles with software, as it’s once again the top recall cause – as it has been for 18 of the past 19 quarters.

Nancy Pham / Informa Pharma Intelligence

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Recalls

More from Policy & Regulation

Dermal Fillers For Décolletage May Gain FDA Approval

 
• By Elizabeth Orr

An upcoming US FDA advisory panel meeting will discuss adding a new indication to allow dermal fillers to be used in the upper chest, or décolletage. Plastic surgeons expect this could drive interest in the procedure, which is already performed off-label.

South Korean Health Ministry Sees Benefits Of Pre-Regulatory Review

 
• By Jung Won Shin

A system of pre-regulatory review consultations for innovative drugs and devices in South Korea has contributed to the accelerated development of such products.

Court Orders US FDA To Return Trial Diversity Action Plan Guidance To Website

 
• By Sue Sutter

HHS and its agencies violated the law by swiftly implementing “sweeping and poorly thought-through directives that ordered the bulk removal of healthcare resources,” including FDA draft guidances on diversity action plans and sex differences in clinical trials, a federal court said.